Vincristine (generic), Oncovin, Vincasar

Vincristine (generic), Oncovin, Vincasar Newswire

Comprehensive Real-Time News Feed for Vincristine (generic), Oncovin, Vincasar.

Results 1 - 20 of 78 in Vincristine (generic), Oncovin, Vincasar

  1. Six-year-old girl tackles cancer with courageRead the original story w/Photo

    13 hrs ago | The Guardian

    Nurse Jana Blanchard enjoys a friendly chat with six-year-old Autumn Newell before the girl received a dose of anti-chemotherapy medication. However, the six-year-old Montague girl was getting ready to head to the hospital, rather than to hit the classroom.

    Comment?

  2. Velcade Now Approved in Combination for Untreated Mantle Cell LymphomaRead the original story w/Photo

    Friday Oct 10 | Lymphoma Info

    According to the manufacturer, Velcade has been approved by the US FDA in combination with other drugs for the treatment of patients with previously untreated mantle cell lymphoma . Velcade has been an approved treatment for relapsed or refractory MCL since 2006.

    Comment?

  3. Targeted mutational profiling of peripheral T-cell lymphoma not...Read the original story

    Friday Sep 26 | Leukemia

    Peripheral T-cell lymphoma not otherwise specified is a diagnosis of exclusion making up the largest fraction of PTCL. Although traditionally considered a ‘wastebasket’ diagnosis, recent gene-expression results suggest the disease comprises two biologic sub-entities characterized by expression of the transcription factors GATA3 or TBX21 and their target genes.

    Comment?

  4. Seattle Genetics Highlights Data for Adcetris plus CHP in PTCL PatientsRead the original story w/Photo

    Thursday Sep 25 | Lymphoma Info

    The biopharmaceutical is highlighting data it will present at the European Society for Medical Oncology Congress this weekend in Madrid. Seattle Genetics will present data constituting an updated two-year durability analysis from a phase I trial testing its antibody drug conjugate Adcetris along with combination chemotherapy in patients with newly diagnosed, CD30 positive, peripheral T-cell lymphoma .

    Comment?

  5. Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to...Read the original story

    Wednesday Sep 24 | Hispanic Business

    ZEVALIN is used in the treatment of non-Hodgkin's lymphoma and MARQIBO is used in the treatment of acute lymphoblastic leukemia . CE melphalan has met the endpoints in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.

    Comment?

  6. Seattle Genetics Highlights Updated Progression-Free Survival and...Read the original story

    Wednesday Sep 24 | Business Wire

    Seattle Genetics, Inc. today highlighted ADCETRIS data to be presented at the 2014 European Society for Medical Oncology Congress being held September 26-30, 2014 in Madrid, Spain. The data include a two-year durability analysis from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of newly diagnosed peripheral T-cell lymphoma patients, also known as mature T-cell lymphoma .

    Comment?

  7. CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of DirectorsRead the original story

    Tuesday Sep 23 | Sys-Con Media

    The appointment was made in connection with the recently announced acquisition of greater , Ph.D., CASI's Chairman of the Board, commented on the appointment, "We are honored to have Dr. Shrotriya on our Board, and look forward to his contributions as the Company continues to expand its pipeline, including our recent addition of MARQIBOA , ZEVALINA and Captisol-Enableda Mephalan. Dr. Shrotriya brings well over thirty years of industry experience, an extensive understanding of the competitive landscape, and a deep insight into the medical science behind current and future drug therapies."

    Comment?

  8. A prospective study of mediastinal gray-zone lymphoma.Read the original story

    Sep 21, 2014 | CiteULike

    Mediastinal B-cell lymphomas present in the mediastinum and are most frequent in young patients. Nodular sclerosis Hodgkin lymphoma and primary mediastinal B-cell lymphoma are the common types, whereas mediastinal gray-zone lymphoma is extremely rare and has pathological features intermediate between NSHL and PMBL.

    Comment?

  9. Spectrum Pharmaceuticals, Inc. Out-Licenses Rights For Greater China...Read the original story

    Sep 18, 2014 | BioSpace

    HENDERSON, Nev. & ROCKVILLE, Md.-- --Spectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, and CASI Pharmaceuticals, Inc. , a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, announce the signing of license agreements whereby CASI has been granted exclusive rights to two of Spectrum Pharmaceuticals' commercial oncology drugs, ZevalinA Injection for intravenous use and MarqiboA for intravenous infusion, and a Phase 3 drug candidate, Captisol-Enableda Melphalan , for development and commercialization in China, including Taiwan, Hong Kong and Macau.

    Comment?

  10. Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to...Read the original story

    Sep 18, 2014 | Sys-Con Media

    CE melphalan has met the endpoints in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum plans to file a New Drug Application with the U.S. Food and Drug Administration for CE melphalan in the second half of 2014.

    Comment?

  11. Spectrum Pharmaceuticals Announces Issue of a New Patent for...Read the original story

    Sep 16, 2014 | Business Wire

    Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8835501, which covers Beleodaq a for Injection on September 16, 2014 with patent term adjustment from May 2026 to October 2027.

    Comment?

  12. China Pharmaceutical University Details Findings in Cancer Therapy...Read the original story

    Sep 10, 2014 | Hispanic Business

    The FRET efficiency of BSA-QD conjugates can reach as high as 24.87% by electrostatic interaction." Our news journalists obtained a quote from the research from , "The higher binding constant Lmol ) and number of binding sites between ZnSe ZnS QDs and BSA demonstrated that the QDs could easily associate to plasma proteins and enhance the transport efficacy of drugs.

    Comment?

  13. Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel...Read the original story

    Sep 9, 2014 | Customer Interaction Solutions

    Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the Phase 3 Go/No-Go decision for SPI-2012, its long acting Granulocyte Stimulating Factor , and is planning for the start of Phase 3 clinical trials next year. "We are pleased with the Phase 2 results that we have seen and have strong conviction that we can have a very exciting novel biologic drug in this very large market," said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

    Comment?

  14. The changing global distribution and prevalence of canine transmissible venereal tumourRead the original story

    Sep 2, 2014 | BioMed Central

    This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

    Comment?

  15. Active equity options trading on openRead the original story w/Photo

    Sep 2, 2014 | Theflyonthewall.com

    Check below for free stories on AAPL;TSLA;TWTR;PBR;GILD;WYNN;NFLX;CELG;FB;BIDU the last two weeks.

    Comment?

  16. Celgene GED301 drug has positive risk/reward ratio in near-term, says BernsteinRead the original story

    Sep 2, 2014 | Theflyonthewall.com

    Celgene GED301 drug has positive risk/reward ratio in near-term, says Bernstein Bernstein believes that the upcoming trial of Celgene's GED0301 drug for Crohn's disease has very little risk in the near-term, while the presentation of results of a study of the drug next month should be positive for the stock.

    Comment?

  17. Spectrum Pharmaceuticals to Present Corporate Update at the Morgan...Read the original story

    Sep 2, 2014 | Freshnews

    Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Morgan Stanley Global Healthcare Conference being ... (more)

    Comment?

  18. Half of African-Americans may need increased dose of HIV drug: simple ...Read the original story w/Photo

    Aug 31, 2014 | Medical News Today

    Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study from Johns Hopkins suggests. 13 comments

  19. Dosage of HIV drug may be ineffective for half of African-AmericansRead the original story w/Photo

    Aug 27, 2014 | Science Daily

    Many African-Americans may not be getting effective doses of the HIV drug maraviroc because they are more likely than European-Americans to inherit functional copies of a protein that speeds the removal of the drug from the body.

    Comment?

  20. Vincristine InjectionRead the original story

    Aug 26, 2014 | ASHP

    Vincasar PFS 1 mg/mL - Teva2 1 mL vial 2 mL vial Vincristine is an antineoplastic vinca alkaloid agent.

    Comment?